about
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trialsA new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centresExtended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathyBortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapseReal-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapyAssociation of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations
P50
Q48194970-96212372-95C8-4885-85DB-51210B48BABDQ89441258-407AC3B7-1CB4-4E1B-B44B-22550E3E7C3BQ89469667-4B18FDFA-68E1-4111-BCAC-90C5CC4AAB7BQ90787146-DB58695C-0D7D-47DF-BEDA-1C436C057B78Q91042002-9A455487-2BF5-4B7D-BAB0-9F37C73E6F15Q92466390-02F33CF0-A07C-401F-8C9F-DB09E34A2471Q93261041-D2F96B4D-0BED-48C2-8AB6-7AA854BD3310Q95636593-3743754B-7C48-4F65-8812-937DB6C2AAB7Q96341717-F8610C38-B3B0-44C9-AB9E-A1BE4AA49761
P50
description
researcher
@en
wetenschapper
@nl
name
Rakesh Popat
@en
Rakesh Popat
@nl
type
label
Rakesh Popat
@en
Rakesh Popat
@nl
prefLabel
Rakesh Popat
@en
Rakesh Popat
@nl
P31
P496
0000-0001-6553-4618